ADVANCED SOLID TUMORS

This early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colorectal, pancreatic, stomach, and head/neck cancers. The main goals are to check safety and find the right dose. About 213 adults …

This early-stage study tests an investigational drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The main goals are to check safety and find the right dose, either alone or with other cancer treatments. About 500 participants w…

This early-phase study tests a new drug, HRS-6209, in 56 adults with advanced solid tumors who have exhausted standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. It is not a cure but aims to control the disease.

This study is testing an experimental drug called Debio 0123 in 66 adults with advanced solid tumors that have grown after standard treatments or have no standard options. The first part finds the safest dose, and the second part checks safety and whether the drug can shrink tumo…

This early-stage study tests an experimental pill, ATV-1601, in people with advanced solid tumors (including certain breast, ovarian, and prostate cancers) that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the …

This study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have certain genetic changes (FGFR2 or FGFR3). The goal is to find the best dose and see if the drug can shrink tumors or slow their growth. About 110 adults w…

This early-stage study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the right dose…

This early-phase study tests a new drug called QTX3544, alone or with another drug (cetuximab), in people with advanced solid tumors that have a specific KRAS G12V mutation. The main goals are to check safety and find the right dose. About 237 adults with cancers that have not re…

This study is for people with advanced solid tumors who are already taking the drug spartalizumab (alone or with other treatments) and are seeing benefits. The main goal is to keep checking for side effects and to allow continued access to the drug. About 120 participants will be…

This early-stage study tests an experimental drug called ABBV-706, alone or with other treatments, in adults with advanced solid tumors like small cell lung cancer and brain tumors. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About…

This study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to see if the combination is safe and whether it can shrink tumors. About 216 adults aged 18 to 75 will …

This early-phase trial is testing an experimental drug called ZN-A-1041, taken as a capsule, for people with advanced HER2-positive solid tumors (including breast cancer) that have spread or come back after prior treatment. The study includes people with or without brain metastas…

This study tests the drug pembrolizumab in about 1,600 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors and to identify biomarkers that predict response. Participants receive pembrolizumab and are m…

This study tests the safety of a new drug, PRL3-ZUMAB, in people with advanced solid tumors or blood cancers that have not responded to standard treatments. It is the first time this drug is given to humans, after showing good tolerance in animals. The goal is to find the safest …

This early-phase study is testing a new form of the chemotherapy drug topotecan, wrapped in a liposome (a tiny fat bubble), to see if it is safe and what dose works best. About 96 adults with advanced solid tumors (including ovarian, cervical, sarcoma, and certain lung and skin c…

This early-stage study tests a new drug called AMG 355, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-phase study tests a new drug called ZW191 in about 145 people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to deliver a cancer-killing agent directly to cells that have a specific marker (folate recep…

This study tests a new drug, ASP1570, in adults with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with other cancer therapies like pembrolizumab, pemetrexed, and carboplatin. The goal is to find a safe dose and see if it helps c…

This early-phase study tests a new drug, BAY 3375968, that targets a protein on immune-suppressing cells to help the body fight advanced solid tumors. About 129 adults with cancers like lung, breast, head and neck, stomach, or melanoma will receive the drug alone or with pembroli…

This early-phase study tests an experimental mRNA medicine (mRNA-4106) in people with advanced solid tumors that have not responded to standard treatments. The medicine is given alone or with another cancer drug (checkpoint inhibitor). The main goal is to check safety and side ef…

This early-phase study tests a new treatment called hV01, a modified virus designed to infect and kill cancer cells while also boosting the immune system. The trial involves 24 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to ch…

This study tests a combination of two drugs, sacituzumab govitecan and berzosertib, in adults with small cell lung cancer or certain resistant cancers. The goal is to find a safe dose and see if the combo can shrink tumors. Participants receive the drugs by vein twice per cycle a…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy can help control advanced solid tumors that have stopped responding to treatment alone. About 57 adults with various advanced or metastatic solid tumors will receive NP137 alongside their …

This study tests a drug called sotorasib, alone or with other cancer treatments, in adults with advanced solid tumors that have a specific KRAS G12C gene change. The main goals are to check safety and how well the drug works at shrinking or controlling tumors. About 610 participa…

This study tests a combination of two experimental drugs, BAT8008 and BAT1308, in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if the drugs can shrink tumors or slow their growth. About 112 participants w…

This early-stage study tests a new drug, BAY 2965501, that aims to activate the body's immune T-cells to fight advanced solid tumors (like certain skin, kidney, stomach, and lung cancers). The study involves about 284 participants and will test the drug alone or combined with oth…